David Goldrich

David Goldrich

Auto-generated profile, based on publicly available information

David Goldrich

Department of Otolaryngology–Head and Neck Surgery Penn State Milton S. Hershey Medical Center and Penn State College of Medicine Hershey 17033 Pennsylvania USA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 October 2024 in Molecular Cancer Research
Verified
Journal Article
Open access
KCKimberly Chan
Kimberly Chan
CTChristopher Tseng
Christopher Tseng
EMEmily Milarachi
Emily Milarachi
DGDavid Goldrich
David Goldrich
LSLisa Schneper
Lisa Schneper
JBJames R. Broach
James R. Broach
Approximately 70% of oropharyngeal squamous carcinomas (OPSCC) are associated with human papillomavirus (HPV). Although patients with HPV-positive (HPV+) tumors generally have better outcomes than those with HPV-negative tumors, a subset of HPV+ positive patients do have poor outcomes. Our previous work suggested that tumors with integrated virus exhibit significantly greater genome-wide genomic instability than those with only episomal viral genomes, and patients with HPV+ OPSCC with episomal viral genomes had better outcomes. To explore the causal relation between viral integration and genomic instability, we have examined the time course of viral integration and genetic instability in tonsillar keratinocytes transformed with HPV16. HPV-infected human tonsil keratinocyte cell lines were continuously passaged, and every fifth passage, some cells were retained for genomic analysis. Whole-genome sequencing and optical genomic mapping confirmed that virus integrated in five of six cell lines while remaining episomal in the sixth. In all lines, genome instability occurred during early passages but essentially ceased following viral integration; however, it continued to occur in later passages in the episomal line. To test tumorigenicity of the cell lines, cells were injected subcutaneously into the flanks of nude mice. A cell line with the integrated virus induced tumors following injection in the nude mouse whereas that with the episomal virus did not. Implications: Genomic instability in HPV OPSCC tumors is not the result of viral integration but likely promotes integration. Moreover, transformants with episomal virus seem to be less tumorigenic than those with integrated virus.

8 January 2026 in OTO Open
Verified
Journal Article
Open access
BSBao Y. Sciscent
Bao Y. Sciscent
HEHanel W. Eberly
Hanel W. Eberly
FLF. Jeffrey Lorenz
F. Jeffrey Lorenz
DGDavid Goldrich
David Goldrich
NGNeerav Goyal
Neerav Goyal
DGDavid Goldenberg
David Goldenberg
Objective: Glucagon‐like peptide 1 receptor agonists (GLP‐1RA) have shown remarkable results in glycemic control for patients with type 2 diabetes (T2DM). While no association has been made, there is a concern for thyroid cancer (TC) from GLP‐1RA. We aimed to study the 5‐year risk of TC in T2DM patients taking GLP‐1RA. Study Design: Retrospective cohort. Setting: TriNetX database. Methods: TriNetX was queried to identify T2DM patients between 2017 and 2019. The 5‐year risk of TC in patients using GLP‐1RA was compared to patients taking sodium‐glucose cotransporter 2 inhibitors (SGLT‐2I), metformin, and dipeptidyl peptidase 4 inhibitors (DPP‐4I) after propensity score matching by demographics and comorbidities. Results: On analysis of T2DM patients taking GLP‐1RA compared to SGLT‐2I, 7736 patients were in each cohort after matching. The 5‐year rate of TC in patients taking GLP‐1RA was 0.30% compared to 0.48% in those taking SGLT‐2I (RR 0.62 (95% CI 0.37‐1.05); P = .07). Analysis of GLP‐1RA versus metformin yielded 5158 patients in each cohort. Patients taking GLP‐1RA had similar rates of TC compared to those taking metformin (0.25% vs 0.39%; RR 0.65 (95% CI 0.32‐1.31); P = .22). A comparison of GLP‐1RA versus DPP‐4I yielded 12,570 patients in each cohort. The rate of TC was not increased in those taking GLP‐1RA compared to those taking DPP‐4I (0.33% vs 0.37%; RR 0.91 (0.60‐1.39); P = .67). Conclusion: T2DM patients taking GLP‐1RA may not have an increased 5‐year risk of TC compared to those taking metformin, SGLT‐2I, or DPP‐4I. Conclusions of long‐term use are limited as most GLP‐1RA were approved within the last decade.

17 June 2026
Verified
Other
Open access
PDF file
KCKimberly Chan
Kimberly Chan
CTChristopher Tseng
Christopher Tseng
EMEmily Milarachi
Emily Milarachi
DGDavid Goldrich
David Goldrich
LSLisa Schneper
Lisa Schneper
JBJames R. Broach
James R. Broach
Table S1. Specifications for thermocycler settings for Anchored PCR.

17 June 2026
Verified
Other
Open access
PDF file
KCKimberly Chan
Kimberly Chan
CTChristopher Tseng
Christopher Tseng
EMEmily Milarachi
Emily Milarachi
DGDavid Goldrich
David Goldrich
LSLisa Schneper
Lisa Schneper
JBJames R. Broach
James R. Broach
Figure S2. WGS and anchored PCR analysis of chromosomal region adjacent to viral integration sites in transformed keratinocytes.

6 February 2025
Verified
Other
Open access
PDF file
KCKimberly Chan
Kimberly Chan
CTChristopher Tseng
Christopher Tseng
EMEmily Milarachi
Emily Milarachi
DGDavid Goldrich
David Goldrich
LSLisa Schneper
Lisa Schneper
JBJames R. Broach
James R. Broach
Table S1. Specifications for thermocycler settings for Anchored PCR.

6 February 2025
Verified
Other
Open access
PDF file
KCKimberly Chan
Kimberly Chan
CTChristopher Tseng
Christopher Tseng
EMEmily Milarachi
Emily Milarachi
DGDavid Goldrich
David Goldrich
LSLisa Schneper
Lisa Schneper
JBJames R. Broach
James R. Broach
Figure S1. Long Range Anchored PCR